Simvastatin: Two decades in a circle

46Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Simvastatin is an agent of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor group of drugs. It is administrated orally once a day in doses of 5-80 mg. Although its main action is to reduce total and low-density lipoprotein (LDL) cholesterol, it is able to reduce triglycerides and increase high-density lipoprotein cholesterol levels, though at a lower extent. Beyond this action, studies enrolled with simvastatin have shown beneficial effect on endothelial function, smooth muscle cell function, hemostasis, vascular wall function, LDL oxidation, and inflammation. All these actions mentioned above are known as pleiotropic effects. In this review, we will present all these effects, as well as the beneficial effects on atherogenesis and the reduction in cardiovascular morbidity and mortality related to simvastatin. © 2008 The Authors.

Cite

CITATION STYLE

APA

Kolovou, G. D., Vasiliadis, I., Anagnostopoulou, K., & Cokkinos, D. V. (2008). Simvastatin: Two decades in a circle. Cardiovascular Therapeutics. https://doi.org/10.1111/j.1527-3466.2008.00047.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free